ReviewBritish journal of cancer2021
Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.
Review in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Pattools‑implemented methylation vector analysis reveals aberrant subtype‑specific methylation in lung cancer across tissue and plasma cfDNA.Clinical and translational medicine · 2026Article
- Utility of RB1 immunohistochemistry for prognostic subtyping of pulmonary large cell neuroendocrine carcinoma.Virchows Archiv : an international journal of pathology · 2026Article
- Patients With Stage III PLCNEC Advocated for Radiotherapy Combined With Chemotherapy While With Stage IV Focus on Individualized Management: Evidence From SEER.Cancer reports (Hoboken, N.J.) · 2026Article
- Optimal Treatment Strategies for Pulmonary Large Cell Neuroendocrine Carcinoma Based on Molecular Subtypes.Journal of clinical medicine · 2026Article
- Case Report: Clinicopathological features of bladder neuroendocrine neoplasm: a retrospective case series of nine cases and literature review.Frontiers in oncology · 2026Article
- Effects of different cancer-directed therapies on mortality of patients with stage I pulmonary large cell neuroendocrine carcinoma: a retrospective cohort study based on the SEER database.Translational cancer research · 2025Article
- Hepatic metastasis of pulmonary large cell neuroendocrine carcinoma: A case report and literature review.The Journal of international medical research · 2025Review
- Prognostic models for large cell neuroendocrine lung carcinoma: a machine learning and regression approach.Translational lung cancer research · 2025Article
- Advancements in lung cancer: molecular insights, innovative therapies, and future prospects.Medical oncology (Northwood, London, England) · 2025Review
- Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Is CK7 a Prognostic Marker in Pulmonary LCNEC? Evidence from a Limited Cohort Study.Journal of personalized medicine · 2025Article
- Case Report: Evolution and targeted therapy of an EGFR-mutant large-cell neuroendocrine carcinoma.Frontiers in oncology · 2025Article
- Frontiers in thoracic oncology: new breakthroughs in molecular targets and immunotherapy.Frontiers in immunology · 2025Review
- Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort.Translational oncology · 2024Article
- Efficacy of combined surgery and pembrolizumab for the treatment of pulmonary large cell carcinoma: a case report.Frontiers in immunology · 2024Article
- The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the Lung.Current oncology (Toronto, Ont.) · 2023Review
- Article
- Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody.Frontiers in immunology · 2023Article
- A Novel Small-Molecule Inhibitor of SREBP-1 Based on Natural Product Monomers Upregulates the Sensitivity of Lung Squamous Cell Carcinoma Cells to Antitumor Drugs.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.